Skip to main content
The Peter Attia Drive
SignalCast Library20 Summaries Available

The Peter Attia Drive

The Peter Attia Drive is the definitive podcast on longevity, healthspan, and peak performance. Dr. Peter Attia interviews world-class scientists and physicians about exercise, nutrition, sleep, pharmacology, and the science of living longer and better. Read AI summaries with the key protocols and research findings from every episode.

New summaries weekly
Latest episode
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
→ WHAT IT COVERS Peter Attia and lipidologist Tom Dayspring examine how the brain manages cholesterol through a system entirely separate from...
Read this summary free →

One free sample — no spam, no commitment.

This Week's Recap

1 episode · Jun 1 – Jun 7

Latest Insights

Key takeaways from recent episodes

#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.

  • **Brain-Peripheral Separation:** The brain's cholesterol system operates completely independently from plasma lipoproteins. ApoB-containing LDL particles are too large to cross the blood-brain barrier, meaning plasma LDL cholesterol levels have zero bearing on brain cholesterol status. A child's LDL can measure 30 mg/dL while the brain grows rapidly, confirming that lowering LDL pharmacologically cannot deprive or damage the brain through cholesterol deficiency.
  • **APOE Genotype and Alzheimer's Risk:** Carrying one E4 allele (roughly 20–25% of the population) approximately doubles Alzheimer's disease risk compared to the E3/E3 wild type. Two E4 copies (1–2% of people) raises risk 8–12 fold. The E4 protein is structurally less functional, impairing cholesterol delivery from astrocyte-produced brain HDL particles to neurons via LDL-related receptors, directly disrupting neuronal membrane integrity and triggering amyloid precursor protein cleavage.

#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

  • **Matching medication to mechanism:** Sleep problems fall into four distinct categories — sleep pressure deficits, circadian misalignment, hyperarousal, and poor sleep architecture — and applying the wrong treatment to the wrong problem causes tolerance, dependence, or worsened sleep. Identifying which system is broken before selecting any tool, behavioral or pharmacological, is the critical first step.
  • **DORAs and Alzheimer's prevention:** Dual orexin receptor antagonists like suvorexant (Belsomra) at 20mg reduced cerebrospinal fluid amyloid-beta by roughly 20% in a 2023 human trial of 38 adults. Unlike Ambien, DORAs preserve slow-wave sleep and the glymphatic waste-clearance system that removes tau and amyloid-beta during deep sleep, making them the most architecturally sound prescription option.

#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they're working for you

  • **Problem Definition Framework:** Before taking any supplement or medication, define three specifics: the measurable metric (e.g., ApoB at 130 mg/dL), the target threshold (below 60 mg/dL), and a time horizon (six months). Vague goals like "more energy" guarantee false positives.
  • **Four-Job Classification System:** Categorize every intervention as disease treatment, symptom relief, risk reduction, or optimization. Each demands a different evidence bar — disease treatment warrants high risk tolerance with strong trial data; optimization warrants maximum skepticism and minimal risk tolerance.

#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results

  • **Pre-test framework:** Before ordering any genetic test, answer four questions: What specifically are you trying to learn? Is genetics the right tool, or can phenotype be measured directly? Will the result change your behavior or treatment? Are you psychologically prepared for either outcome? This framework prevents the common mistake of generating data without generating clarity or actionable next steps.
  • **Consumer SNP tests vs. clinical panels:** Direct-to-consumer genotyping products like 23andMe scan only hundreds of thousands of common SNPs and tested only three BRCA variants originally, while thousands of pathogenic BRCA mutations exist. A negative consumer result does not rule out hereditary cancer risk. For meaningful cancer genetic assessment, clinical-grade panel testing from a CLIA-certified laboratory is required, not a consumer product.

Recent Episode Summaries

20 AI-powered summaries available

100 min episode3 min read

→ WHAT IT COVERS Peter Attia and lipidologist Tom Dayspring examine how the brain manages cholesterol through a system entirely separate from peripheral circulation, covering APOE genotype variants (E2/E3/E4), their mechanistic links to Alzheimer's disease risk, how amyloid and tau pathology connect to neuronal cholesterol imbalance, and what statins, ezetimibe, omega-3 fatty acids, and the CETP inhibitor obecetrapib do—or don't do—inside the brain.

54 min episode3 min read

→ WHAT IT COVERS Peter Attia maps the full landscape of sleep pharmacology, covering four root causes of poor sleep, then systematically evaluating benzodiazepines, z-drugs, DORAs, melatonin, trazodone, antihistamines, and supplements including glycine, magnesium, and ashwagandha against those specific mechanisms. → KEY INSIGHTS - **Matching medication to mechanism:** Sleep problems fall into four distinct categories — sleep pressure deficits, circadian misalignment, hyperarousal, and poor...

13 min episode3 min read

→ WHAT IT COVERS Peter Attia outlines a decision framework for evaluating medications and supplements, covering problem definition, intervention classification into four job categories, evidence thresholds, and why most longevity supplements are speculative optimization rather than proven risk reduction. → KEY INSIGHTS - **Problem Definition Framework:** Before taking any supplement or medication, define three specifics: the measurable metric (e.g.

62 min episode3 min read

→ WHAT IT COVERS Peter Attia builds a practical framework for evaluating genetic testing across cardiovascular disease, cancer, neurodegeneration, and pharmacogenetics. He distinguishes high-value tests like BRCA panels from low-value consumer SNP products, explains why phenotype measurement often outperforms genotype prediction, and outlines four questions to ask before ordering any genetic test.

7 min episode3 min read

→ WHAT IT COVERS Peter Attia covers colorectal cancer screening, explaining why CRC is uniquely preventable, how colonoscopy functions as both detection and prevention, the rise of early-onset cases in younger adults, and how to evaluate noninvasive screening alternatives. → KEY INSIGHTS - **Preventability window:** Colorectal cancer progresses from normal tissue to malignancy over a decade or more, creating a long intervention window.

8 min episode3 min read

→ WHAT IT COVERS Peter Attia's AMA #84 addresses eight health topics including family health history analysis, cardiovascular disease prevention gaps, metabolic health in overweight individuals, strength training efficiency, dementia risk reduction, NAD supplements, and hydration strategies. → KEY INSIGHTS - **Family History vs. Genetic Testing:** Most major diseases like heart disease, diabetes, and cancer arise from polygenic backgrounds, meaning no single gene causes them.

53 min episode3 min read

→ WHAT IT COVERS Peter Attia presents a framework for scientific thinking, covering why it is biologically unnatural for humans, how 50 million years of primate social cognition conflicts with 400 years of empiricism, and five practical principles for evaluating claims, updating beliefs, and identifying trustworthy experts in health and beyond. → KEY INSIGHTS - **Certainty as a red flag:** When you feel certain about a claim, treat that feeling as a signal to pause and audit your reasoning.

46 min episode3 min read

→ WHAT IT COVERS Peter Attia examines why prostate cancer deaths are rising despite available screening tools, presenting data showing current USPSTF guidelines are built on a fatally contaminated study, and outlining a modern detection framework using PSA velocity, PSA density, contrast-free MRI, and transperineal biopsy to catch lethal cancers early.

22 min episode3 min read

→ WHAT IT COVERS Peter Attia presents a structured framework for evaluating gray market peptides—including SS-31, Melanotan II, CJC-1295, and BPC-157—by examining mechanism of action, human safety data, efficacy evidence, and whether FDA-approved alternatives exist before considering any peptide for personal use. → KEY INSIGHTS - **Evaluation Framework:** Apply five questions to any peptide before use: Does a defined mechanistic pathway exist? What downstream effects occur in healthy humans?

42 min episode3 min read

→ WHAT IT COVERS Peter Attia examines aging clocks—epigenetic tools that estimate biological age via DNA methylation patterns—analyzing two studies: the DO Health randomized trial testing omega-3, vitamin D, and exercise across four clocks, and a brain MRI study measuring pace of aging to predict dementia risk and mortality. → KEY INSIGHTS - **Epigenetic Clock Mechanics:** Aging clocks measure methylation at CpG sites—locations where cytosine links to guanine on the DNA backbone—across hundreds...

18 min episode3 min read

→ WHAT IT COVERS Peter Attia addresses real-world longevity application across decades of life, ranking the four chronic disease "horsemen" by difficulty to combat, and explaining why cancer and neurodegeneration demand the most concern despite cardiovascular disease remaining the top killer. → KEY INSIGHTS - **Age-based training strategy:** In your teens and twenties, deliberately push physical limits and overtrain to build a higher VO2 max ceiling that persists for decades.

52 min episode3 min read

→ WHAT IT COVERS Peter Attia examines obicetrapib, a CETP inhibitor drug that lowers LDL cholesterol by 30–60% on top of existing statin therapy, and analyzes the Broadway biomarker study showing it significantly attenuates p-tau 217 progression — a key Alzheimer's marker — with the strongest signal in APOE4 homozygous carriers. → KEY INSIGHTS - **CETP inhibitor history:** Four predecessor drugs failed for two distinct reasons: off-target toxicity (torcetrapib raised blood pressure; anacetrapib...

126 min episode3 min read

→ WHAT IT COVERS Lisa Mosconi discusses why Alzheimer's disease affects twice as many women as men, revealing it begins in midlife during menopause rather than old age. She presents brain imaging research showing women develop Alzheimer's pathology earlier than men, explores estrogen receptor density changes through menopause, examines menopausal hormone therapy timing and formulations, and introduces the CARE initiative targeting fifty percent reduction in women's Alzheimer's risk by 2050.

127 min episode3 min read

→ WHAT IT COVERS Peter Attia and Layne Norton examine whether seed oils pose unique health risks compared to other dietary fats, analyzing randomized controlled trials, Mendelian randomization studies, LDL oxidation mechanisms, and industrial processing methods to evaluate cardiovascular disease outcomes. → KEY INSIGHTS - **Trans Fat Confounding in Early Studies:** The Minnesota Coronary Experiment and Sydney Heart Study showed increased mortality with polyunsaturated fats, but margarine used...

38 min episode3 min read

→ WHAT IT COVERS Peter Attia provides a comprehensive guide to cardiorespiratory training, explaining how zone two and VO2 max training impact longevity, the science behind lactate thresholds, and how to structure workouts based on available training time. → KEY INSIGHTS - **VO2 max mortality impact:** Being in the bottom 25% for VO2 max creates four to five times higher mortality risk versus top 3%, while moving from second to third quartile reduces mortality 50-75%.

131 min episode3 min read

→ WHAT IT COVERS Abbie Smith-Ryan discusses evidence-based training and nutrition strategies for women across life stages, from puberty through menopause, covering menstrual cycle optimization, perimenopause muscle changes, pregnancy training, supplement protocols, and resistance training prioritization for metabolic health. → KEY INSIGHTS - **Bone density ceiling:** Women reach peak bone density around age 19, making childhood and adolescent exercise critical for lifelong skeletal health.

139 min episode3 min read

→ WHAT IT COVERS James Clear explains his four-stage habit formation framework (cue, craving, response, reward) and how to build good habits through making them obvious, attractive, easy, and satisfying, while breaking bad habits by inverting these principles. → KEY INSIGHTS - **Four Laws Framework:** Build habits by making them obvious (visible cues), attractive (appealing anticipation), easy (low friction), and satisfying (immediate reward).

99 min episode3 min read

→ WHAT IT COVERS Arthur Brooks explains happiness as three macronutrients—enjoyment, satisfaction, and meaning—rather than fleeting feelings. He provides frameworks for managing success addiction, practicing metacognition, and building sustainable happiness through deliberate choices over reactive emotions in modern life. → KEY INSIGHTS - **Enjoyment vs Pleasure:** Enjoyment requires pleasure plus two elements—people and memory.

22 min episode3 min read

→ WHAT IT COVERS Peter Attia addresses common listener questions about longevity interventions, covering exercise prioritization, ApoB management, blood pressure targets, metabolic health assessment, hormone replacement therapy, diagnostic screening protocols, and time-efficient training strategies for health span optimization. → KEY INSIGHTS - **Exercise as primary intervention:** Cardiovascular fitness and muscular strength show greater mortality benefits than smoking cessation, hypertension...

128 min episode3 min read

→ WHAT IT COVERS Dom D'Agostino discusses ketogenic diets, exogenous ketones, and hyperbaric oxygen as metabolic therapies. Topics include achieving nutritional ketosis, managing electrolytes during transition, differences between ketone salts versus esters, applications for epilepsy and cancer, and carnivore diets as ketogenic variants. → KEY INSIGHTS - **Ketogenic Diet Efficacy for Epilepsy:** Two-thirds of pediatric epilepsy patients who fail multiple drug therapies respond therapeutically...

Monday morning, inbox, done.

Pick your shows, and start the week knowing what happened in your world.

1

Pick the Podcasts You Care About

Choose from 200+ curated shows or add any public RSS feed.

2

AI Reads Every New Episode

Key arguments, surprising data points, and frameworks worth stealing — pulled automatically.

3

One Email, Every Monday

A curated brief for each episode, with links to listen if something grabs you.

Resources mentioned on The Peter Attia Drive

Books, tools, and gear cited by guests across episodes we've summarized.

SignalCast may earn commission on purchases via affiliate links on each resource page.

Explore More

Get a free sample digest

See what your Monday email looks like — real AI summaries, no account needed.

One free sample — no spam, no commitment.